Antibodies to Plasminogen Activator Inhibitor-1 (PAI-1) and Uses Thereof

Abstract

The invention provides antibodies that specifically bind to Plasminogen Activator Inhibitor type-1 (PAI-1). The invention also provides pharmaceutical compositions, as well as nucleic acids encoding anti-PAI-1 antibodies, recombinant expression vectors and host cells for making such antibodies, or fragments thereof. Methods of using antibodies to modulate PAI-1 activity or detect PAI-1, either in vitro or in vivo, are also provided. The disclosure further provides methods of making antibodies that specifically bind to PAI-1 in the active conformational state.

1 - 15 . (canceled) 
     
     
         16 . An isolated monoclonal antibody or fragment thereof that competitively inhibits the binding of an anti-PAI-1 antibody or antigen binding fragment thereof, wherein the anti-PAI-1 antibody or antigen binding fragment thereof comprises:
 (a) a heavy chain variable region comprising a heavy chain CDR1 region comprising SEQ ID NO: 34, a heavy chain CDR2 region comprising SEQ ID NO: 33, and a heavy chain CDR3 region comprising SEQ ID NO: 32; and a light chain variable region comprising a light chain CDR1 region comprising SEQ ID NO: 37, a light chain CDR2 region comprising SEQ ID NO: 145 or SEQ ID NO: 36, and a light chain CDR3 region comprising SEQ ID NO: 35; or   (b) a heavy chain variable region comprising a heavy chain CDR1 region comprising SEQ ID NO: 22, a heavy chain CDR2 region comprising SEQ ID NO: 21, and a heavy chain CDR3 region comprising SEQ ID NO: 20; and a light chain variable region comprising a light chain CDR1 region comprising SEQ ID NO: 25, a light chain CDR2 region comprising SEQ ID NO: 24, and a light chain CDR3 region comprising SEQ ID NO: 23; or   (c) a heavy chain variable region comprising a heavy chain CDR1 region comprising SEQ ID NO: 28, a heavy chain CDR2 region comprising SEQ ID NO: 27, and a heavy chain CDR3 region comprising SEQ ID NO: 26; and a light chain variable region comprising a light chain CDR1 region comprising SEQ ID NO: 31, a light chain CDR2 region comprising SEQ ID NO: 30, and a light chain CDR3 region comprising SEQ ID NO: 29; or   (d) a heavy chain variable region comprising a heavy chain CDR1 region comprising SEQ ID NO: 40, a heavy chain CDR2 region comprising SEQ ID NO: 39, and a heavy chain CDR3 region comprising SEQ ID NO: 38; and a light chain variable region comprising a light chain CDR1 region comprising SEQ ID NO: 43, a light chain CDR2 region comprising SEQ ID NO: 42, and a light chain CDR3 region comprising SEQ ID NO: 41; or   (e) a heavy chain variable region comprising a heavy chain CDR1 region comprising SEQ ID NO: 46, a heavy chain CDR2 region comprising SEQ ID NO: 45, and a heavy chain CDR3 region comprising SEQ ID NO: 44; and a light chain variable region comprising a light chain CDR1 region comprising SEQ ID NO: 49, a light chain CDR2 region comprising SEQ ID NO: 48, and a light chain CDR3 region comprising SEQ ID NO: 47; or   (f) a heavy chain variable region comprising a heavy chain CDR1 region comprising SEQ ID NO: 52, a heavy chain CDR2 region comprising SEQ ID NO: 51, and a heavy chain CDR3 region comprising SEQ ID NO: 50; and a light chain variable region comprising a light chain CDR1 region comprising SEQ ID NO: 55, a light chain CDR2 region comprising SEQ ID NO: 54, and a light chain CDR3 region comprising SEQ ID NO: 53; or   (g) a heavy chain variable region comprising a heavy chain CDR1 region comprising SEQ ID NO: 58, a heavy chain CDR2 region comprising SEQ ID NO: 57, and heavy chain CDR3 region comprising SEQ ID NO: 56; and a light chain variable region comprising a light chain CDR1 region comprising SEQ ID NO: 61, a light chain CDR2 region comprising SEQ ID NO: 60, and a light chain CDR3 region comprising SEQ ID NO: 59; or   (h) a heavy chain variable region comprising a heavy chain CDR1 region comprising SEQ ID NO: 64, a heavy chain CDR2 region comprising SEQ ID NO: 63, and a heavy chain CDR3 region comprising SEQ ID NO: 62; and a light chain variable region comprising a light chain CDR1 region comprising SEQ ID NO: 67, a light chain CDR2 region comprising SEQ ID NO: 66, and a light chain CDR3 region comprising SEQ ID NO: 65; or   (i) a heavy chain variable region comprising a heavy chain CDR1 region comprising SEQ ID NO: 70, a heavy chain CDR2 region comprising SEQ ID NO: 69, and a heavy chain CDR3 region comprising SEQ ID NO: 68; and a light chain variable region comprising a light chain CDR1 region comprising SEQ ID NO: 73, a light chain CDR2 region comprising SEQ ID NO: 72, and a light chain CDR3 region comprising SEQ ID NO: 71; or   (j) a heavy chain variable region comprising a heavy chain CDR1 region comprising SEQ ID NO: 76, heavy chain CDR2 region comprising SEQ ID NO: 75, and a heavy chain CDR3 region comprising SEQ ID NO: 74; and a light chain variable region comprising a light chain CDR1 region comprising SEQ ID NO: 79, a light chain CDR2 region comprising SEQ ID NO: 78, and a light chain CDR3 region comprising SEQ ID NO: 77.   
     
     
         17 . An isolated monoclonal antibody or fragment thereof that competitively inhibits the binding of an anti-PAI-1 antibody or antigen binding fragment thereof, wherein the anti-PAI-1 antibody or antigen binding fragment thereof comprises:
 (a) a heavy chain framework region and a heavy chain variable region comprising SEQ ID NO: 86, and   (b) a light chain framework region and a light chain variable region comprising SEQ ID NO: 93.   
     
     
         18 . The isolated monoclonal antibody or fragment of  claim 16  that competitively inhibits the binding of an anti-PAI-1 antibody or antigen binding fragment thereof, wherein the anti-PAI-1 antibody or antigen binding fragment thereof comprises a heavy chain variable region comprising SEQ ID NO: 6 and a light chain variable region comprising SEQ ID NO: 7. 
     
     
         19 . An isolated monoclonal antibody or fragment thereof that competitively inhibits the binding of an anti-PAI-1 antibody or antigen binding fragment thereof, wherein the anti-PAI-1 antibody or antigen binding fragment thereof comprises:
 (a) a heavy chain having a heavy chain variable region comprising SEQ ID NO: 82, and a light chain having a light chain variable region comprising SEQ ID NO: 91; or   (b) a heavy chain having a heavy chain variable region comprising SEQ ID NO: 83, and a light chain having a light chain variable region comprising SEQ ID NO: 92; or   (c) a heavy chain having a heavy chain variable region comprising SEQ ID NO: 84, and a light chain having a light chain variable region comprising SEQ ID NO: 93; or   (d) a heavy chain having a heavy chain variable region comprising SEQ ID NO: 85, and a light chain having a light chain variable region comprising SEQ ID NO: 91; or   (e) a heavy chain having a heavy chain variable region comprising SEQ ID NO: 85, and a light chain having a light chain variable region comprising SEQ ID NO: 93; or   (f) a heavy chain having a heavy chain variable region comprising SEQ ID NO: 86, and a light chain having a light chain variable region comprising SEQ ID NO: 94; or   (g) a heavy chain having a heavy chain variable region comprising SEQ ID NO: 87, and a light chain having a light chain variable region comprising SEQ ID NO: 95; or   (h) a heavy chain having a heavy chain variable region comprising SEQ ID NO: 88, and a light chain having a light chain variable region comprising SEQ ID NO: 96; or   (i) a heavy chain having a heavy chain variable region comprising SEQ ID NO: 89, and a light chain having a light chain variable region comprising SEQ ID NO: 97; or   (j) a heavy chain having a heavy chain variable region comprising SEQ ID NO: 90, and a light chain having a light chain variable region comprising SEQ ID NO: 98; or   (k) a heavy chain having a heavy chain variable region comprising SEQ ID NO: 86, and a light chain having a light chain variable region comprising SEQ ID NO: 95; or   (l) a heavy chain having a heavy chain variable region comprising SEQ ID NO: 89, and a light chain having a light chain variable region comprising SEQ ID NO: 93; or   (m) a heavy chain having a heavy chain variable region comprising SEQ ID NO: 89, and a light chain having a light chain variable region comprising SEQ ID NO: 95.   
     
     
         20 . A method of restoring plasmin generation comprising administering to a subject in need thereof orally, parenterally by a solution for injection, by inhalation, or topically, a pharmaceutically effective amount of an isolated monoclonal antibody or fragment thereof that competitively inhibits the binding of an anti-PAI-1 antibody or antigen binding fragment thereof of  claim 16 . 
     
     
         21 . The method of  claim 20 , wherein the method treats a condition comprising increased levels of fibrotic tissue. 
     
     
         22 . The method of  claim 21 , wherein the condition is fibrosis, systemic sclerosis, interstitial lung disease, chronic lung disease, chronic kidney disease, peripheral limb ischemia, acute ischemic stroke with and without thrombolysis, or stent restenosis. 
     
     
         23 . The method of  claim 21 , wherein the method treats a condition comprising skin fibrosis, lung fibrosis, idiopathic pulmonary fibrosis, liver fibrosis, or kidney fibrosis. 
     
     
         24 . The method of  claim 20 , wherein the method treats a condition comprising venous and arterial thrombosis, deep vein thrombosis, or disseminated intravascular coagulation thrombosis. 
     
     
         25 . A preparation for parenteral administration comprising a pharmaceutically effective amount of an isolated monoclonal antibody or fragment thereof that competitively inhibits the binding of an anti-PAI-1 antibody or antigen binding fragment thereof, wherein the anti-PAI-1 antibody or antigen binding fragment is the anti-PAI-1 antibody or antigen binding fragment of  claim 16 . 
     
     
         26 . The preparation of  claim 25 , wherein the preparation is in the form of a sterile powder or a sterile injectable solution. 
     
     
         27 . A container comprising the sterile injectable solution of  claim 26 , wherein the container comprises an ampoule, a bag, a bottle, a syringe, or a vial. 
     
     
         28 . A kit, comprising a preparation according to  claim 26  and a label or a package insert. 
     
     
         29 . A preparation for parenteral administration comprising a pharmaceutically effective amount of an isolated monoclonal antibody or fragment thereof that competitively inhibits the binding of an anti-PAI-1 antibody or antigen binding fragment thereof, wherein the anti-PAI-1 antibody or antigen binding fragment is the anti-PAI-1 antibody or antigen binding fragment of  claim 17 . 
     
     
         30 . A preparation for parenteral administration comprising a pharmaceutically effective amount of an isolated monoclonal antibody or fragment thereof that competitively inhibits the binding of an anti-PAI-1 antibody or antigen binding fragment thereof, wherein the anti-PAI-1 antibody or antigen binding fragment is the anti-PAI-1 antibody or antigen binding fragment of  claim 18 . 
     
     
         31 . A preparation for parenteral administration comprising a pharmaceutically effective amount of an isolated monoclonal antibody or fragment thereof that competitively inhibits the binding of an anti-PAI-1 antibody or antigen binding fragment thereof, wherein the anti-PAI-1 antibody or antigen binding fragment is the anti-PAI-1 antibody or antigen binding fragment of  claim 19 .